Evidence map›Paper›PMID 33532004›Full record

ArticleDisease markers

Role of the Gas6/TAM System as a Disease Marker and Potential Drug Target.

Pier Paolo Sainaghi, Mattia Bellan, Alessandra Nerviani

Abstract readEditorial
In one paragraph

Article in Disease markers. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Observational
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Pier Paolo SainaghiDepartment of Translational Medicine, Università del Piemonte Orientale UPO, Novara, Italy.ORCID https://orcid.org/0000-0001-8322-9158
Mattia BellanDepartment of Translational Medicine, Università del Piemonte Orientale UPO, Novara, Italy.ORCID https://orcid.org/0000-0003-1488-8736
Alessandra NervianiIRCAD, Interdisciplinary Research Center of Autoimmune Diseases, Novara, Italy.ORCID https://orcid.org/0000-0003-4064-4014

Funding

Versus Arthritis 21890
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Molecular Targeted TherapyArthritis, RheumatoidAxl Receptor Tyrosine KinaseBiomarkersc-Mer Tyrosine KinaseGene ExpressionGrowth Arrest-Specific Protein 6Hematologic NeoplasmsHumansIdiopathic Pulmonary FibrosisImmunologic FactorsIntercellular Signaling Peptides and ProteinsLiver CirrhosisLupus Erythematosus, SystemicProto-Oncogene ProteinsReceptor Protein-Tyrosine KinasesAXL protein, humanAxl Receptor Tyrosine KinaseBiomarkersc-Mer Tyrosine KinaseGrowth Arrest-Specific Protein 6Immunologic FactorsIntercellular Signaling Peptides and ProteinsMERTK protein, humanProto-Oncogene ProteinsReceptor Protein-Tyrosine KinasesTYRO3 protein, human

Identifiers

PMID33532004
PMCPMC7834835

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.